This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
by Kinjel Shah
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $75.49, marking a -0.83% move from the previous day.
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
by Zacks Equity Research
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
by Zacks Equity Research
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
by Zacks Equity Research
The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
by Zacks Equity Research
Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.
Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)
by Zacks Equity Research
FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer
by Zacks Equity Research
Merck (MRK) is seeking approval for label expansion of Keytruda in Europe to include first-line treatment of certain patients with advanced or metastatic urothelial carcinoma.
Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL
by Zacks Equity Research
FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $78.30 in the latest trading session, marking a +1.18% move from the prior day.
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
by Zacks Equity Research
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA
by Zacks Equity Research
Gilead's (GILD) regulatory application for breast cancer drug has been validated by the regulatory body in Europe.
Bristol-Myers (BMY) Announces Results From Opdivo Combo Study
by Zacks Equity Research
Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill
by Zacks Equity Research
Pfizer (PFE) starts an early-stage U.S. study on an oral COVID-19 antiviral candidate.
Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer
by Zacks Equity Research
The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $76.27, marking a -1.6% move from the previous day.
Roche's (RHHBY) Tecentriq Meets Primary Goal in Lung Cancer Study
by Zacks Equity Research
Roche's (RHHBY) Tecentriq meets primary endpoint of disease-free survival at the interim analysis in lung cancer patients.
Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA
by Kinjel Shah
WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $77.30, moving +0.64% from the previous trading session.
Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.
Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments
by Zacks Equity Research
Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.
Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation
by Zacks Equity Research
Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.